Peter J Ferguson
Overview
Explore the profile of Peter J Ferguson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alotaibi F, Rytelewski M, Figueredo R, Zareardalan R, Zhang M, Ferguson P, et al.
Eur J Immunol
. 2020 Jan;
50(5):695-704.
PMID: 31943150
CD5 is expressed on T cells and a subset of B cells (B1a). It can attenuate TCR signalling and impair CTL activation and is a therapeutic targetable tumour antigen expressed...
2.
Ferguson P, Vincent M, Koropatnick J
J Pharmacol Exp Ther
. 2017 Oct;
364(1):46-54.
PMID: 29061656
Although cancer cell genetic instability contributes to characteristics that mediate tumorigenicity, it also contributes to the tumor-selective toxicity of some chemotherapy drugs. This synthetic lethality can be enhanced by inhibitors...
3.
Rytelewski M, Maleki Vareki S, Mangala L, Romanow L, Jiang D, Pradeep S, et al.
Oncotarget
. 2016 Mar;
7(15):20825-39.
PMID: 26959114
Human tumor heterogeneity promotes therapeutic failure by increasing the likelihood of resistant cell subpopulations. The PARP-1 inhibitor olaparib is approved for use in BRCA-mutated ovarian cancers but BRCA2-reversion mutations lead...
4.
Maleki Vareki S, Chen D, Cresce C, Ferguson P, Figueredo R, Pampillo M, et al.
PLoS One
. 2015 Nov;
10(11):e0143435.
PMID: 26579709
Indoleamine 2,3-dioxygenase-1 (IDO) is an immune regulatory enzyme expressed by most human tumors. IDO levels in tumor cells correlate with increased metastasis and poor patient outcome and IDO is linked...
5.
Ferguson P, Sykelyk A, Figueredo R, Koropatnick J
Tumori
. 2015 Oct;
102(1):31-9.
PMID: 26429639
Aims And Background: In light of the need for more selective anticancer therapy, much work has been directed at developing compounds or biological agents that target functions specific to cancer...
6.
Cresce C, Figueredo R, Rytelewski M, Maleki Vareki S, Way C, Ferguson P, et al.
Oncotarget
. 2015 Jun;
6(26):22397-409.
PMID: 26087398
Nucleoside metabolism enzymes are determinants of chemotherapeutic drug activity. The nucleoside salvage enzyme deoxycytidine kinase (dCK) activates gemcitabine (2', 2'-difluoro-2'-deoxycytidine) and is negatively regulated by deoxycytidine triphosphate (dCTP). Reduction of...
7.
Rytelewski M, Tong J, Buensuceso A, Leong H, Maleki Vareki S, Figueredo R, et al.
Mol Oncol
. 2014 Jun;
8(8):1429-40.
PMID: 24974076
Tumor cells have unstable genomes relative to non-tumor cells. Decreased DNA integrity resulting from tumor cell instability is important in generating favorable therapeutic indices, and intact DNA repair mediates resistance...
8.
Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson P, Vincent M, et al.
Oncotarget
. 2014 May;
5(9):2778-91.
PMID: 24784564
Indoleamine 2,3-dioxygenase-1 (IDO) is an immunosuppressive molecule expressed by most human tumors. IDO levels correlate with poor prognosis in cancer patients and IDO inhibitors are under investigation to enhance endogenous...
9.
Rytelewski M, Ferguson P, Maleki Vareki S, Figueredo R, Vincent M, Koropatnick J
Mol Ther Nucleic Acids
. 2013 Mar;
2:e78.
PMID: 23481354
A high mutation rate leading to tumor cell heterogeneity is a driver of malignancy in human cancers. Paradoxically, however, genomic instability can also render tumors vulnerable to therapeutic attack. Thus,...
10.
Ferguson P, Brisson A, Koropatnick J, Vincent M
Cancer Lett
. 2008 Nov;
274(2):279-89.
PMID: 18986763
N,N-diethyl-2-[4-(phenylmethyl)phenoxyl]ethanamine (tesmilifene), a tamoxifen derivative with antihistamine activity, greatly enhanced the survival of doxorubicin-treated, advanced stage breast cancer patients in a phase III trial. However, the molecular basis of tesmilifene...